Following this transaction Joseph Bonaccorsi’s holding in the company was increased by 4.84% to a total of $2.22 million.
Currently, Akorn has an average volume of 2.53M.
Based on 4 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $8.00, reflecting a 98.0% upside.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akorn, Inc. operates as a niche pharmaceutical company that develops, manufactures and markets generic and prescription pharmaceuticals, as well as, animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health segments.